Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2008-11-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/13543780802493366PMID 19012502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Updates on p53: modulation of p53 degradation as a therapeutic approach

  2008influential reference
• Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.

  2008cited by this paper
• Mutated and non‐mutated TP53 as targets in the treatment of leukaemia

  2008cited by this paper
• Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

  2008influential reference
• JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies

  2008cited by this paper
• MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2

  2008cited by this paper
• Unlocking the Mdm2-p53 loop: Ubiquitin is the key

  2008influential reference
• The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis

  2008influential reference
• p53: a guide to apoptosis.

  2008influential reference
• Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation

  2008influential reference
• Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.

  2007influential reference
• p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?

  2007cited by this paper
• MDM2 inhibitors for cancer therapy.

  2007influential reference
• Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.

  2007cited by this paper
• Inhibitors of the interaction between MDM2 and p53

  2007cited by this paper
• Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

  2007cited by this paper
• MDM2 and MDM4: p53 regulators as targets in anticancer therapy.

  2007cited by this paper
• Alpha-Helix Mimetics: Progress Toward Effective Modulation of Protein-Protein Complexes

  2007influential reference
• Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53

  2007cited by this paper
• Inhibitors of the MDM2-p53 interaction as anticancer drugs

  2007cited by this paper
• Small molecule protein-protein inhibitors for the p53-MDM2 interaction.

  2007influential reference
• Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.

  2006cited by this paper
• Strategies for therapeutic targeting of the p53 pathway in cancer

  2006influential reference
• Patented small molecule inhibitors of p53–MDM2 interaction

  2006influential reference
• Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

  2006influential reference
• Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

  2006cited by this paper
• The P53 pathway: what questions remain to be explored?

  2006influential reference
• Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.

  2006cited by this paper
• Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.

  2006cited by this paper
• Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells*

  2006cited by this paper
• Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.

  2006cited by this paper
• Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

  2006cited by this paper
• Adenoviral gene therapy in head and neck cancer.

  2006cited by this paper
• MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

  2006influential reference
• Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists.

  2006cited by this paper
• Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

  2006influential reference
• Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.

  2006cited by this paper
• Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

  2006cited by this paper
• Substituted 1,4‐Benzodiazepine‐2,5‐diones as α‐Helix Mimetic Antagonists of the HDM2‐p53 Protein–Protein Interaction

  2006cited by this paper
• MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin*

  2006cited by this paper
• Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors.

  2006cited by this paper
• Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

  2005cited by this paper
• Mdmx as an essential regulator of p53 activity.

  2005cited by this paper
• Targeting protein–protein interactions for cancer therapy

  2005influential reference
• Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists.

  2005cited by this paper
• Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

  2005cited by this paper
• Structure-based design of potent non-peptide MDM2 inhibitors.

  2005cited by this paper
• Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs*

  2005cited by this paper
• p53 Activation by small molecules: application in oncology.

  2005influential reference
• p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53

  2005cited by this paper
• p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53.

  2005cited by this paper
• NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro

  2005cited by this paper
• Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.

  2005cited by this paper
• Strategies for targeting protein-protein interactions with synthetic agents.

  2005influential reference
• MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

  2005influential reference
• PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis

  2005cited by this paper
• 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.

  2005cited by this paper
• MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

  2005cited by this paper
• Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

  2005cited by this paper
• Small molecule inhibitors of p53/MDM2 interaction.

  2005cited by this paper
• Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.

  2005cited by this paper
• Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction.

  2005cited by this paper
• Targeting the p53–MDM2 interaction to treat cancer

  2004influential reference
• A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells.

  2004cited by this paper
• Mdmx and Mdm2: Brothers in Arms?

  2004cited by this paper
• Antisense approaches in prostate cancer

  2004cited by this paper
• A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004influential reference
• Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

  2004cited by this paper
• Binding of an inhibitor of the p53/MDM2 interaction to MDM2.

  2003cited by this paper
• INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.

  2003cited by this paper
• The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.

  2003cited by this paper
• Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

  2003cited by this paper
• The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis

  2002cited by this paper
• Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors

  2002cited by this paper
• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  2002cited by this paper
• The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

  2002cited by this paper
• Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53*

  2002cited by this paper
• The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway.

  2002cited by this paper
• Characterization of the p53-rescue drug CP-31398 in vitro and in living cells

  2002cited by this paper
• Study of the cytotoxic effect of a peptidic inhibitor of the p53–hdm2 interaction in tumor cells

  2002cited by this paper
• Gene targets of antisense therapies in breast cancer

  2002cited by this paper
• Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp.

  2001cited by this paper
• HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.

  2001cited by this paper
• Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.

  2001cited by this paper
• Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.

  2001cited by this paper
• Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53

  2001cited by this paper
• Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

  2000cited by this paper
• Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides.

  2000cited by this paper
• A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

  2000cited by this paper
• Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models.

  2000cited by this paper
• Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression

  1999cited by this paper
• Pharmacological rescue of mutant p53 conformation and function.

  1999cited by this paper
• p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53

  1999cited by this paper
• MDM2 oncogene as a target for cancer therapy: An antisense approach.

  1999cited by this paper
• Molecular characterization of the hdm2-p53 interaction.

  1997cited by this paper
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2

  1997cited by this paper
• Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

  1997cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper

• Computational Identification of Marine Natural Products as Potential MDM2 Inhibitors Using E‐Pharmacophore‐Based Virtual Screening, MD Simulations, MM‐GBSA, DFT, PCA, and FEL Analysis

  2025cites this paper
• Multi-Step Synthesis of Chimeric Nutlin–DCA Compounds Targeting Dual Pathways for Treatment of Cancer

  2025cites this paper
• Enzymatic Desymmetrisation of Prochiral meso-1,2-Disubstituted-1,2-Diaminoethane for the Synthesis of Key Enantioenriched (−)-Nutlin-3 Precursor

  2024cites this paper
• Sequence-Controlled Spherical Nucleic Acids: Gene Silencing, Encapsulation, and Cellular Uptake

  2023cites this paper
• Exploring the Significance of p53 Gene in Lung Cancer: Etiological Factors, Clinical Implications, and Therapeutic Approaches

  2023cites this paper
• Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction

  2022cites this paper
• Phe19 Modification of HDM2-p53 PPI Inhibitors to Alleviate CYP3A4 Metabolism/Mechanism-based Inhibition Liability.

  2022cites this paper
• The roles of E3 ligases in Hepatocellular carcinoma.

  2022influential citation
• Repurposed Drugs in Gastric Cancer

  2022cites this paper
• Silver-Catalyzed Synthesis of CF3-Substituted 2-Imidazolines

  2022cites this paper
• Prognostic Implications of EGFR, p53, p16, Cyclin D1, and Bcl‐2 in Head and Neck Squamous Cell Carcinoma (HNSCC)

  2020cites this paper
• Synthesis of 2-Imidazolines via Palladium-Catalyzed Cyclization Reaction of 2,3-Allenyl Amines and Aryl Iodides

  2020cites this paper
• The X-linked trichothiodystrophy-causing gene RNF113A links the spliceosome to cell survival upon DNA damage

  2020cites this paper
• RNA modifications and cancer

  2020cites this paper
• In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2

  2020cites this paper
• Acute depletion of telomerase components dkc1 and nop10 induces oxidative stress and disrupts ribosomal biogenesis via npm1 and activation of the p53 pathway.

  2020cites this paper
• Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease

  2020cites this paper
• An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction

  2019cites this paper
• Proteomic investigating the cooperative lethal effect of EGFR and MDM2 inhibitors on ovarian carcinoma.

  2018cites this paper
• Interested in publishing with us ? Contact book

  2018cites this paper
• Rare ER protein misfolding-mistrafficking disorders: Therapeutic developments.

  2017cites this paper
• Reviving the guardian of the genome: Small molecule activators of p53

  2017cites this paper
• Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents

  2017cites this paper
• Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model

  2017cites this paper
• Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues

  2017cites this paper
• Anticancer activity of CT-p19LC, a synthetic peptide derived from the bacterial protein azurin

  2017cites this paper
• N-(Hetero)aryl-2-imidazolines: an emerging privileged motif for contemporary drug design

  2017cites this paper
• The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.

  2016cites this paper
• The role of p53 in cancer drug resistance and targeted chemotherapy

  2016cites this paper
• Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.

  2016cites this paper
• Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

  2016cites this paper
• Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.

  2016cites this paper
• ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice.

  2016cites this paper
• Role of E3 ubiquitin ligases in insulin resistance

  2016cites this paper
• Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds

  2016cites this paper
• Chemical Variations on the p53 Reactivation Theme

  2016cites this paper
• Targeting PRAS40 for multiple diseases.

  2016cites this paper
• The Chan-Evans-Lam N-Arylation of 2-Imidazolines.

  2016cites this paper
• Disruption of protein–protein interactions: hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target – survivin

  2016cites this paper
• Biologically active compounds based on the privileged 2-imidazoline scaffold: The world beyond adrenergic/imidazoline receptor modulators.

  2015cites this paper
• Foldamers as Anticancer Therapeutics: Targeting Protein–Protein Interactions and the Cell Membrane

  2015cites this paper
• Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.

  2015cites this paper
• Small-molecule inhibitors of the Myc oncoprotein.

  2015cites this paper
• P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.

  2015cites this paper
• Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties

  2015cites this paper
• Acute skeletal muscle wasting in the critically ill

  2014cites this paper
• Peptides containing β-amino acid patterns: challenges and successes in medicinal chemistry.

  2014cites this paper
• MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation

  2014cites this paper
• Proteasome Inhibitors Versus E3 Ligase Inhibitors for Cancer Therapy

  2014cites this paper
• Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.

  2014cites this paper
• Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.

  2014cites this paper
• Substituted piperidines as HDM2 inhibitors.

  2014cites this paper
• Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

  2013cites this paper
• Regulation of the HDM2-p53 pathway by ribosomal protein L6 in response to ribosomal stress

  2013cites this paper
• Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.

  2013cites this paper
• RNF2/Ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development

  2013cites this paper
• Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5

  2013cites this paper
• Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2.

  2013cites this paper
• The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1

  2013cites this paper
• Chromenes: potential new chemotherapeutic agents for cancer.

  2013cites this paper
• Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer

  2013cites this paper
• Microwave assisted solid phase synthesis of highly functionalized N-alkylated oligobenzamide α-helix mimetics.

  2013cites this paper
• Role of E3 ubiquitin ligases in lung cancer.

  2013cites this paper
• Role of murine double minute (MDM)-2 in kidney injury and repair

  2013cites this paper
• Chapter Fourteen - Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy

  2013cites this paper
• The Novel Anti-cancer Agent JNJ-26854165 Induces Cell Death Through Inhibition of Cholesterol Transport and Degradation of ABCA1.

  2013cites this paper
• Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction.

  2012cites this paper
• MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel

  2012cites this paper
• Proline-mediated Proteasomal Degradation of the Prostate-specific Tumor Suppressor NKX3.1*

  2012cites this paper
• History of protein–protein interactions: From egg‐white to complex networks

  2012cites this paper
• 15 Predicting and Dissecting High-order Molecular Complexity by Information-driven Biomolecular Docking

  2012cites this paper
• Erioflorin Stabilizes the Tumor Suppressor Pdcd4 by Inhibiting Its Interaction with the E3-ligase β-TrCP1

  2012cites this paper
• Antimicrobial activity of carbon nanotubes.

  2012cites this paper
• Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells

  2012cites this paper
• Molecular Dynamic Simulation Insights into the Normal State and Restoration of p53 Function

  2012cites this paper
• Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.

  2011cites this paper
• Virtual Screening for DNA Repair Inhibitors

  2011cites this paper
• Synthesis of chondramide A analogues with modified β-tyrosine and their biological evaluation.

  2011cites this paper
• Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.

  2011cites this paper
• Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors.

  2011cites this paper
• Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

  2011cites this paper
• Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)

  2011cites this paper
• Quantitative Cell-based Protein Degradation Assays to Identify and Classify Drugs That Target the Ubiquitin-Proteasome System

  2011cites this paper
• MDM2 inhibitors for pancreatic cancer therapy.

  2010cites this paper
• Therapeutic Targeting of Myc.

  2010cites this paper
• N-alkylated oligoamide alpha-helical proteomimetics.

  2010cites this paper
• DNA damage response to the Mdm2 inhibitor nutlin-3.

  2010cites this paper
• MYCN oncoprotein targets and their therapeutic potential.

  2010cites this paper
• MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines

  2010cites this paper
• The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias

  2010cites this paper
• Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.

  2010cites this paper
• Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database

  2010cites this paper
• Designing Focused Chemical Libraries Enriched in Protein-Protein Interaction Inhibitors using Machine-Learning Methods

  2010cites this paper
• Molecular Interaction Fields and 3D-QSAR Studies of p53-MDM2 Inhibitors Suggest Additional Features of Ligand-Target Interaction

  2010cites this paper
• Strategies for the identification of ubiquitin ligase inhibitors.

  2010cites this paper
• Directly probing the racemization of imidazolines by vibrational circular dichroism: kinetics and mechanism.

  2010cites this paper
• Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction

  2009cites this paper
• Novel ways to sensitise gastrointestinal cancer to apoptosis

  2009cites this paper
• Musings on genome medicine: cancer genetics and the promise of effective treatment

  2009cites this paper
• MDM2/MDMX inhibitor peptide: WO2008106507

  2009cites this paper